Updated product information for healthcare professionals and patients regarding the small risk of severe acute pancreatitis in patients taking GLP-1s.
Similar Posts
If you take a GLP-1 medicine and have been hospitalised by acute pancreatitis, the Yellow Card Biobank wants to hear from you
GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro and Wegovy
The MHRA and the global flu vaccine: How the UK is helping shape the world’s flu vaccine
Ensuring the seasonal flu vaccine is ready, safe and effective involves months of international planning, testing and collaboration
Clinical trials for medicines: apply for authorisation in the UK
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
The new Innovative Licensing and Access Pathway welcomes first investigational products
Developers work with the NHS, the medicines regulator and the UK health technology assessment bodies from the early stages of clinical development, as part of the Innovative Licensing and Access Pathway.
Class 3 Medicines Recall: Glenmark Pharmaceuticals Europe Limited, Fingolimod Glenmark 0.5 mg Hard Capsules, EL(26)A/02
Glenmark Pharmaceuticals Europe Limited is recalling one batch after stability testing showed out-of-specification results. The batch is being recalled as a precautionary measure following test results that showed a delay in capsule dissolution.
Transparency data: Medicines and Healthcare products Regulatory Agency spending over £25,000: 2025 to 2026
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.